NEW YORK (GenomeWeb News) – Diagnostics developer Sirius Genomics will collaborate with Vanderbilt University to study patients in a biomarker study for a drug aimed at treating severe sepsis, the company said today.

The pharmacogenomics company will work with Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study to continue development of a diagnostic to assess responsiveness to recombinant human activated Protein C. The drug is sold by Eli Lilly under the trade name Xigris.